Eton gained exclusive U.S. rights to a seizure treatment, creating a new sales opportunity if required approvals arrive. The upfront fee, possible milestone payments, sales royalties, and approval limits temper but do not outweigh that opportunity.
The license gives Eton a possible new product to sell in the United States. Tentative approval for some age groups makes the opportunity more concrete, but sales still depend on required approvals. Eton paid an upfront fee and may owe milestone payments and a share of sales. Those costs matter, but the exclusive rights and potential sales make the deal favorable overall.
Aquestive receives an upfront fee, possible milestone payments, and sales royalties, and remains the exclusive supplier. Giving up U.S. sales rights is a cost, but these payments and the initial 20-year supply term support its business.
Follow Eton Pharmaceuticals, Inc. (ETON) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ETON